During the AAPS National Biotech Conference 2025, pharmaphorum’s Jonah Comstock sat down with Eric Luellen, the founder and CTIO of Turing Biosciences. Luellen shared the company's ambitious mission ...

What if we could reprogramme the TME itself? Cutting-edge research suggests that engineered mesenchymal stem cells (MSCs) ...

European Commission President Ursula von der Leyen has lost a lawsuit attempting to force her to disclose text messages with ...

It seems Novo Nordisk is leaving no stone unturned as it builds a pipeline of drug candidates for obesity and cardiometabolic ...

GSK has agreed to pay $1.2 billion upfront to acquire rights to efimosfermin from Cambridge, Massachusetts-based Boston ...

The drive revolves around a "10-for-one" policy laid out in a Trump executive order at the end of January, which demanded ...

Andrew Witty has resigned as chief executive of US health conglomerate UnitedHealth Group, as the company pulled its ...

That’s it for 2025’s Q1 clinical trials round-up. If you have a study that could fit the bill for our next column, please ...

The progress made in liver disease research to date presents an opportunity for further advancements in the near future.

Reducing exposure to medicines is always a good thing if similar clinical outcomes can be achieved, and the study suggests it ...